[HTML][HTML] Bortezomib paradigm shift in myeloma
DJ McConkey - Blood, 2009 - Elsevier
Blood, 2009•Elsevier
Bortezomib paradigm shift in myeloma - ScienceDirect Skip to main contentSkip to article
Elsevier logo Journals & Books Search RegisterSign in View PDF Download full issue
Search ScienceDirect Blood Blood Volume 114, Issue 5, 30 July 2009, Pages 931-932
Journal home page for Blood LYMPHOID NEOPLASIA Bortezomib paradigm shift in
myeloma Author links open overlay panel David J. McConkey 1 Show more Share Cite https://doi.org/10.1182/blood-2009-06-223230
Get rights and content Under an Elsevier user license open archive Bortezomib's …
Elsevier logo Journals & Books Search RegisterSign in View PDF Download full issue
Search ScienceDirect Blood Blood Volume 114, Issue 5, 30 July 2009, Pages 931-932
Journal home page for Blood LYMPHOID NEOPLASIA Bortezomib paradigm shift in
myeloma Author links open overlay panel David J. McConkey 1 Show more Share Cite https://doi.org/10.1182/blood-2009-06-223230
Get rights and content Under an Elsevier user license open archive Bortezomib's …
Bortezomib's unprecedented antitumor activity in myeloma has long been attributed to NF-κB inhibition. A new study from the group that put the drug on the map directly challenges this assumption.
Elsevier